News And Events
-
The Inauguration and Technology Cooperation Signing Ceremony of the Joint R&D Center for Artificial Intelligence and Active Pharmaceutical Ingredient (API) Biosynthesis Successfully Held
On the morning of August 16, the inauguration and technology cooperation signing ceremony for the Joint R&D Center for Artificial Intelligence and Active Pharmaceutical Ingredient (API) Biosynthesis was successfully held at Building 16 of Yuelu Mountain Laboratory. The center was jointly esta...Read more -
Can AI and Traditional Chinese Medicine Work Together to Develop New APIs?
On August 16, the Joint R&D Center for Artificial Intelligence and Active Pharmaceutical Ingredient (API) Biosynthesis was officially established by Hunan Yineng Pharma Co., Ltd. (Yineng Pharma), Dongting Laboratory, Hunan Academy of Agricultural Sciences, Hunan Agricultural University, and Y...Read more -
AI-Powered TCM Leader: Yineng Pharma Named to Top 100 Innovative Medicine List
Introduction: A Major Milestone in Digital TCM Innovation The highly anticipated 2026 Future Healthcare 100 Conference recently concluded in Shanghai, spotlighting the pioneers driving the next generation of life sciences. A major highlight of the event was the official release of the “Top ...Read more -
Yineng Pharma’s “Intelligent Large Model for TCM Formula Development and Application” Selected for Provincial AI Large Model Recognition List
TCM AI Large Models and AI-Driven Herbal Drug Development: A Paradigm Shift in Progress What Is a TCM AI Large Model? A TCM AI large model refers to a domain-specific intelligent system built on large language model (LLM) architectures, enhanced with deep integration of traditional Chinese medic...Read more -
Zhenwu Tang Granules (Class 3.1 Classical Formula) Approved in China: A Milestone in Modern TCM Development
Regulatory Breakthrough in Classical Chinese Medicine Innovation Recently, according to the National Medical Products Administration (NMPA), the traditional Chinese medicine (TCM) new drug Zhenwu Tang Granules, jointly supported by research from Hunan Yineng Biopharmaceuticals Co., Ltd. and submi...Read more -
Refusing the “Delisting Risk”: 20 Days Left Before the Compliance Deadline — How Yunyao Zhiyi Supports TCM Approval Renewal
The countdown has already started. For many Chinese patent medicine companies, July 1, 2026 is no longer just another regulatory date. Inside the industry, it is increasingly being called a “survival checkpoint.” Products that have long relied on vague or incomplete safety labeling may soon lose ...Read more -
Another Major Milestone | First Class 1.1 Innovative Traditional Chinese Medicine of the New Year Receives IND Approval in China
Edited by Professor Yi Recently, according to the official website of the Center for Drug Evaluation (CDE), the Class 1.1 innovative traditional Chinese medicine (TCM) Qingxue Baidu Pills successfully obtained the Notification of Approval for Drug Clinical Trials in Chi...Read more -
YINENG PHARMA Chairman Yi Yueneng Appears at the 2026 J.P. Morgan Healthcare Conference
In January, as the tides of the Pacific signal new directions for the global biopharmaceutical industry, the 44th J.P. Morgan Healthcare Conference successfully concluded on January 15, 2026, in San Francisco. As one of the largest healthcare investment and industry collaboration events worldwide...Read more -
Jointly Exploring New Paths for TCM Modernization | Chairman Gong Hongjia of Jiadao Capital and His Entourage Visit Yineng Pharmaceutical for Inspection and Exchange
On November 2nd, Gong Hongjia, Chairman of Jiadao Capital, led his team to visit Hunan Yineng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Yineng Pharmaceutical”) for inspection and exchange, aiming to conduct an in-depth exploration of the innovative practices and develop...Read more -
Good News | Yineng Pharmaceutical’s Class 3.1 New TCM Drug – Classic Formula Linggui Zhugan Decoction Granules – Approved for Marketing
Recently, Hunan Yineng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Yineng Pharmaceutical”) has received the Drug Registration Certificate for Linggui Zhugan Decoction Granules approved and issued by the National Medical Products Administration (NMPA). The product has been...Read more -
Happy New Year! 2026
The start of 2026 is a moment to reflect—and to look ahead with hope. We are grateful for the opportunity to serve you in 2025 and eager to grow together in the year to come. Thank you for your partnership. May 2026 bring you strength, innovation, and lasting success.Read more -
Good News｜ MedGence was approved to establish Hunan Provincial Engineering and Technology Research Center
2023-12-27 Recently, the Hunan Provincial Department of Science and Technology issued a public notice on the establishment of the 2023 Hunan Provincial Engineering Technology Research Center. MedGence was approved to establish the Hunan Provincial Artificial Intelligence...Read more
